Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18762301 | COMPOSITIONS AND METHODS FOR EPIGENETIC REGULATION OF HBV GENE EXPRESSION | July 2024 | October 2025 | Allow | 15 | 2 | 1 | No | Yes |
| 18443045 | METHODS FOR REGULATING NITROGEN METABOLISM DURING THE PRODUCTION OF ETHANOL FROM CORN BY METABOLICALLY ENGINEERED YEAST STRAINS | February 2024 | March 2026 | Abandon | 25 | 1 | 0 | No | No |
| 18390011 | APPARATUS AND METHODS USING TETHERED ENZYMES FOR THE DETECTION OF THE ENZYMATIC ACTIVITY OF BIOMARKERS | December 2023 | April 2025 | Abandon | 16 | 1 | 1 | No | No |
| 18537221 | MICROPEPTIDES AND USES THEREOF | December 2023 | August 2025 | Allow | 21 | 1 | 1 | No | No |
| 18485455 | VIRAL TREATMENT | October 2023 | February 2026 | Abandon | 28 | 0 | 1 | No | No |
| 18373659 | METHODS FOR PRODUCTION OF OXYGENATED TERPENES | September 2023 | October 2025 | Allow | 24 | 1 | 1 | No | No |
| 18043265 | BACTERICIDE | February 2023 | February 2026 | Abandon | 36 | 0 | 1 | No | No |
| 18019660 | KERATINOLYTIC POLYPEPTIDES AND METHODS OF USE | February 2023 | October 2025 | Allow | 32 | 0 | 0 | No | No |
| 18154531 | SYSTEMS AND METHODS FOR MANUFACTURING A SILK FIBROIN SOLUTION AND POWDERS CONTAINING SILK FIBROIN | January 2023 | August 2025 | Allow | 31 | 1 | 0 | No | No |
| 18095468 | COMPOSITION AND METHOD FOR OMEGA-3 AND PLANT FLAVONOIDS FOR INCREASING HDL CHOLESTEROL AND DECREASING LDL CHOLESTEROL AND TRIGLYCERIDE LEVELS | January 2023 | February 2026 | Abandon | 38 | 0 | 1 | No | No |
| 18015232 | CROSSLINKED HYDROGEL FOR IMMUNE CHECKPOINT BLOCKADE DELIVERY | January 2023 | December 2025 | Allow | 35 | 1 | 0 | No | No |
| 18145807 | Protease and Binding Polypeptide for O-Glycoproteins | December 2022 | September 2025 | Allow | 33 | 1 | 1 | No | No |
| 18002435 | PREPARATIONS CONTAINING BERRY EXTRACTS FOR USE IN THE PROPHYLAXIS AND/OR TREATMENT OF VIRAL INFECTIONS CAUSED BY CORONAVIRIDAE | December 2022 | January 2026 | Abandon | 37 | 0 | 1 | No | No |
| 18065645 | AUTOMATIC DISHWASHING COMPOSITION COMPRISING A PROTEASE | December 2022 | November 2025 | Allow | 35 | 1 | 0 | No | No |
| 18058451 | COLLAGEN HYDROLYSATE COMPRISING GPCR LIGAND PEPTIDE | November 2022 | December 2025 | Allow | 36 | 1 | 0 | No | No |
| 18055373 | Method for Degumming and Refining of Vegetable Oil | November 2022 | February 2026 | Abandon | 39 | 2 | 1 | No | No |
| 18053482 | BLOOD SUBSTITUTES COMPRISING HEMOGLOBIN AND METHOGS OF MAKING | November 2022 | November 2025 | Allow | 36 | 3 | 0 | Yes | No |
| 18052454 | Xylanase Variants and Polynucleotides Encoding Same | November 2022 | December 2025 | Allow | 37 | 3 | 1 | No | No |
| 17962560 | APPLICATION OF HYPERICUM JAPONICUM THUMB EXTRACT IN THE PREPARATION OF A DRGU AGAINST THE BLUE-EAR DISEASE | October 2022 | January 2026 | Abandon | 39 | 1 | 0 | No | No |
| 18045214 | METHODS AND COMPOSITIONS FOR SYNTHESIZING IMPROVED SILK FIBERS | October 2022 | November 2025 | Allow | 37 | 1 | 1 | No | No |
| 17817028 | FLOWER ESSENCE-CONTAINING MEDICAMENTS | August 2022 | February 2026 | Abandon | 42 | 1 | 1 | Yes | No |
| 17865546 | Topical Lip Balm Composition and Method of Use Thereof for Healing Cold Sores | July 2022 | January 2026 | Abandon | 42 | 2 | 0 | No | No |
| 17852456 | Cleaning Compositions and Uses Thereof | June 2022 | September 2025 | Allow | 38 | 2 | 1 | No | Yes |
| 17773516 | URATE OXIDASE-ALBUMIN CONJUGATE, PREPARATION METHOD THEREOF, AND USE THEREOF | April 2022 | April 2025 | Allow | 36 | 1 | 1 | No | No |
| 17731941 | MICROCAPSULE AND PRODUCTION METHOD THEREOF | April 2022 | March 2026 | Abandon | 47 | 0 | 1 | No | No |
| 17771419 | A METHOD OF SNAKE FISH EXTRACTION | April 2022 | February 2026 | Abandon | 46 | 1 | 0 | No | No |
| 17709166 | DOSING AND ADMINISTRATION OF RECOMBINANT L-ASPARAGINASE | March 2022 | October 2025 | Allow | 42 | 4 | 0 | No | No |
| 17700237 | Enzyme And Application Thereof | March 2022 | October 2025 | Allow | 43 | 1 | 0 | No | No |
| 17624670 | PROKARYOTIC EXPRESSION SYSTEM AND METHODS OF USING THE SAME | January 2022 | October 2025 | Allow | 46 | 1 | 0 | No | No |
| 17279564 | Protein Fiber Production Method | March 2021 | November 2025 | Allow | 56 | 4 | 1 | Yes | No |
| 16893153 | FORMULATIONS AND DOSES OF PEGYLATED URICASE | June 2020 | October 2025 | Allow | 60 | 5 | 1 | No | Yes |
| 16406538 | Concentrated Aqueous Silk Fibroin Solution and Use Thereof | May 2019 | May 2021 | Allow | 24 | 3 | 0 | No | No |
| 16325583 | METHOD FOR REDUCING AMMONIUM AND LACTATE PRODUCTION IN CHO CELLS | February 2019 | November 2020 | Allow | 21 | 1 | 0 | No | No |
| 16081645 | COMPOSITIONS AND METHODS FOR MAKING TERPENOID INDOLE ALKALOIDS | August 2018 | March 2021 | Allow | 31 | 2 | 1 | No | No |
| 16103473 | MICROPARTICLES FOR CELL DISRUPTION AND/OR BIOMOLECULE RECOVERY | August 2018 | February 2020 | Allow | 18 | 1 | 0 | No | No |
| 15761469 | Fungal production of FDCA | March 2018 | February 2021 | Allow | 35 | 2 | 1 | No | No |
| 15399339 | COMPOSITIONS AND METHODS FOR IDENTIFYING PROTEASE INHIBITORS | January 2017 | February 2020 | Allow | 37 | 1 | 1 | No | No |
| 15313329 | PROTEIN EXTRACTION METHODS | November 2016 | November 2018 | Allow | 24 | 1 | 1 | No | No |
| 15127181 | THE USE OF GLYCEROL WITH LIMITED FEED OF CARBOHYDRATES FOR FERMENTATION | September 2016 | April 2019 | Allow | 31 | 2 | 0 | No | No |
| 14913337 | MICROPARTICLES FOR CELL DISRUPTION AND/OR BIOMOLECULE RECOVERY | February 2016 | May 2018 | Allow | 27 | 1 | 0 | No | No |
| 15005964 | METHOD FOR ANALYZING PSA, AND A METHOD FOR DISTINGUISHING PROSTATE CANCER FROM PROSTATIC HYPERTROPHY USING THAT METHOD FOR ANALYZING PSA | January 2016 | September 2018 | Allow | 32 | 3 | 0 | Yes | No |
| 14905157 | VULCANISAETAL PHOSPHOTRIESTERASE-LIKE LACTONASES (PLL) HAVING ENHANCED PROPERTIES AND THE USES THEREOF | January 2016 | September 2018 | Allow | 32 | 2 | 1 | No | No |
| 14983448 | METHOD FOR PREPARING CHITOSAN-COATED MAGNETIC NANOPARTICLES FOR PROTEIN IMMOBILIZATION | December 2015 | February 2018 | Allow | 26 | 1 | 0 | No | No |
| 14981723 | CHEMICAL MODIFICATION OF GLUCOSE OXIDASE AND ITS APPLICATION TO BIOSENSORS | December 2015 | September 2018 | Allow | 33 | 2 | 1 | No | No |
| 14896905 | 3HP TOLERANCE | December 2015 | May 2018 | Allow | 29 | 1 | 0 | No | No |
| 14948161 | BIOSENSORS THAT DETECT NAD+ | November 2015 | July 2018 | Allow | 32 | 1 | 1 | No | No |
| 14840084 | MATRIX COMPOSED OF A NATURALLY-OCCURRING PROTEIN BACKBONE CROSS LINKED BY A SYNTHETIC POLYMER AND METHODS OF GENERATING AND USING SAME | August 2015 | March 2017 | Allow | 19 | 1 | 0 | No | No |
| 14769245 | MATERIALS AND METHODS FOR REMOVING ENDOTOXINS FROM PROTEIN PREPARATIONS | August 2015 | March 2017 | Allow | 19 | 1 | 0 | No | No |
| 14819028 | NON-INVASIVE DIAGNOSTIC METHOD FOR THE EVALUATION OF INTESTINAL LACTASE DEFICIENCY (HYPOLACTASIA) | August 2015 | October 2016 | Allow | 14 | 0 | 0 | No | No |
| 14791872 | ELECTROSPUN NANOFIBROUS MEMBRANES AND DISPOSABLE GLUCOSE BIOSENSOR | July 2015 | April 2017 | Allow | 21 | 1 | 1 | No | No |
| 14758339 | Human Serum Albumin Binding Compounds and Fusion Proteins Thereof | June 2015 | June 2017 | Allow | 23 | 1 | 1 | Yes | No |
| 14422397 | SOLID DISHWASHING DETERGENT WITH IMPROVED PROTEASE PERFORMANCE | June 2015 | June 2018 | Allow | 39 | 4 | 0 | Yes | No |
| 14741259 | METHODS, REAGENTS AND CELLS FOR BIOSYNTHESIZING COMPOUNDS | June 2015 | May 2017 | Allow | 23 | 1 | 0 | No | No |
| 14119319 | CELL-DIRECTED SYNTHESIS OF MULTIFUNCTIONAL NANOPATTERNS AND NANOMATERIALS | December 2014 | September 2016 | Allow | 34 | 1 | 1 | No | No |
| 14348757 | METHOD FOR FORMING A REVERSIBLE PROTEIN NANOCLUSTER USING LIGHT IN A CELL | November 2014 | March 2017 | Allow | 35 | 1 | 1 | No | No |
| 14396317 | USE OF N-ACETYLNEURAMINIC ACID ALDOLASE IN CATALYTIC SYNTHESIS OF N-ACETYLNEURAMINIC ACID | October 2014 | October 2016 | Allow | 24 | 2 | 0 | No | No |
| 14455699 | PSYCHROPHILIC ENZYMES COMPOSITIONS AND METHODS FOR MAKING AND USING SAME | August 2014 | March 2017 | Allow | 31 | 3 | 1 | No | No |
| 14376884 | COATED DEVICES AND METHODS FOR COATING | August 2014 | June 2017 | Allow | 34 | 1 | 1 | Yes | No |
| 14451255 | MULTI-PHASED, BIODEGRADABLE AND OESTEOINTEGRATIVE COMPOSITE SCAFFOLD FOR BIOLOGICAL FIXATION OF MUSCULOSKELETAL SOFT TISSUE TO BONE | August 2014 | April 2016 | Allow | 21 | 1 | 0 | No | No |
| 14330703 | PROCESS FOR THE PURIFICATION OF RECOMBINANT ALBUMIN | July 2014 | September 2016 | Allow | 26 | 2 | 0 | No | No |
| 14203476 | Method of Forming Non-Immunogenic Hydrophobic Protein Nanoparticles, and Uses Therefor | March 2014 | November 2016 | Allow | 32 | 2 | 0 | No | No |
| 14187070 | PEPTIDE INHIBITORS OF PROTEIN KINASE C | February 2014 | February 2016 | Allow | 24 | 1 | 0 | No | No |
| 14180975 | Method for Stable Gene-Amplification in a Bacterial Host Cell | February 2014 | June 2016 | Allow | 28 | 2 | 0 | No | No |
| 14003560 | BIODEGRADABLE ELECTROCONDUCTING NANOWIRE, METHOD OF MANUFACTURE AND USES THEREOF | February 2014 | September 2016 | Allow | 37 | 1 | 1 | No | No |
| 14109508 | KDR AND VEGF/KDR BINDING PEPTIDES AND THEIR USE IN DIAGNOSIS AND THERAPY | December 2013 | June 2016 | Allow | 30 | 2 | 0 | Yes | No |
| 14106033 | Methods of Producing 7-Carbon Chemicals via CoA-Dependent Carbon Chain Elongation Associated with Carbon Storage | December 2013 | May 2017 | Allow | 42 | 4 | 1 | Yes | No |
| 14124849 | POLYHEDRAL CAGE-CONTAINING MESOPOROUS METAL-ORGANIC FRAMEWORKS AS PLATFORM FOR BIOCATALYSIS, METHODS OF MAKING THESE FRAMEWORKS, AND METHODS OF USING THESE FRAMEWORKS | December 2013 | March 2016 | Allow | 27 | 1 | 0 | No | No |
| 14085645 | KDR AND VEGF/KDR BINDING PEPTIDES AND THEIR USE IN DIAGNOSIS AND THERAPY | November 2013 | March 2016 | Allow | 28 | 1 | 0 | No | No |
| 14078113 | Templated Native Silk Smectic Gels | November 2013 | March 2016 | Allow | 28 | 1 | 0 | No | No |
| 14033012 | Cell Modeling of Heme Deficiency using Ferrochelatase Mutations | September 2013 | February 2014 | Allow | 5 | 0 | 0 | Yes | No |
| 13965328 | Method of Bonding Gold Nanoparticles with Diethylenetriamine Pentaacetic Acid | August 2013 | November 2015 | Allow | 27 | 1 | 0 | No | No |
| 13951354 | Isotopically-Labeled Proteome Standards | July 2013 | November 2016 | Allow | 39 | 3 | 0 | Yes | No |
| 13948505 | TARGETING VECTOR-PHOSPHOLIPID CONJUGATES | July 2013 | February 2016 | Allow | 31 | 1 | 0 | No | No |
| 13882035 | PROTEIN-BASED CONJUGATES AND SELF-ASSEMBLED NANOSTRUCTURES | July 2013 | January 2016 | Allow | 33 | 1 | 0 | No | No |
| 13867914 | Method For Increasing The Activity Of Lysosomal Enzymes | April 2013 | June 2014 | Allow | 13 | 1 | 0 | No | No |
| 13817305 | Method for Activating Catalyst Using Photothermal Nanomaterials | April 2013 | December 2015 | Allow | 34 | 1 | 0 | No | No |
| 13808357 | Non-Leachable Magnetic Cross-Linked Enzyme Aggregate | March 2013 | February 2016 | Allow | 37 | 2 | 0 | No | No |
| 13770924 | ANTIMICROBIAL PEPTIDES AND DERIVED METAPEPTIDES | February 2013 | May 2015 | Allow | 27 | 1 | 1 | No | No |
| 13649595 | RECOMBINANT HUMAN NAGLU PROTEIN AND USES THEREOF | October 2012 | October 2016 | Allow | 48 | 3 | 1 | No | No |
| 13505280 | METHOD FOR ANALYZING PSA, AND A METHOD FOR DISTINGUISHING PROSTATE CANCER FROM PROSTATIC HYPERTROPHY USING THAT METHOD FOR ANALYZING PSA | July 2012 | October 2015 | Allow | 42 | 2 | 1 | Yes | No |
| 13519877 | BIOLUMINESCENT PACKAGING | June 2012 | June 2016 | Allow | 47 | 3 | 1 | Yes | No |
| 13448362 | SYSTEMS AND METHODS OF REMOVING AND MANAGING HEAVY METALS | April 2012 | December 2015 | Allow | 44 | 1 | 1 | No | No |
| 13408432 | Combinatorial DNA Library for Producing Modified N-Glycans In Lower Eukaryotes | February 2012 | April 2014 | Allow | 26 | 2 | 1 | No | No |
| 13404536 | PROTEIN NANOCARRIERS FOR TOPICAL DELIVERY | February 2012 | August 2015 | Allow | 42 | 2 | 0 | No | No |
| 13322951 | BIOSENSORS UTILIZING INK JET-PRINTED BIOMOLECULE COMPATIBLE SOL GEL INKS AND USES THEREOF | February 2012 | May 2015 | Allow | 42 | 3 | 1 | No | No |
| 13350097 | NON-INVASIVE DIAGNOSTIC METHOD FOR THE EVALUATION OF INTESTINAL LACTASE DEFICIENCY (HYPOLACTASIA) | January 2012 | May 2015 | Allow | 40 | 2 | 1 | No | No |
| 13260691 | DICARBOXYLIC ACID PRODUCTION PROCESS | November 2011 | September 2015 | Allow | 48 | 3 | 1 | No | No |
| 13277003 | MalPEG-Hb Conjugate-Containing Compositions for Delivering Nitric Oxide (NO) to Cells | October 2011 | May 2015 | Allow | 43 | 2 | 0 | No | No |
| 13263296 | COENZYME Q10 NANOPARTICLES, PREPARATION METHOD THEREOF AND COMPOSITION CONTAINING SAID NANOPARTICLES | October 2011 | March 2014 | Allow | 29 | 1 | 1 | No | No |
| 13237327 | METHOD FOR EXTRACTION AND PURIFICATION OF RECOMBINANT PROTEINS FROM TRANSGENIC PLANTS | September 2011 | February 2014 | Allow | 29 | 1 | 1 | No | No |
| 13229033 | RECOMBINANT CLOSTRIDIA THAT FIX CO2 AND CO AND USES THEREOF | September 2011 | February 2014 | Allow | 29 | 1 | 1 | No | No |
| 13221417 | Compositions and methods for prion decontamination | August 2011 | December 2012 | Allow | 16 | 1 | 0 | No | No |
| 13218685 | COMPOSITIONS AND METHODS FOR COUNTERACTING EFFECTS OF REACTIVE OXYGEN SPECIES AND FREE RADICALS | August 2011 | February 2014 | Allow | 30 | 1 | 0 | No | No |
| 13217337 | METHOD FOR REMOVING UNMODIFIED HEMOGLOBIN FROM CROSS-LINKED HEMOGLOBIN SOLUTIONS INCLUDING POLYMERIC HEMOGLOBIN WITH A HIGH TEMPERATURE SHORT TIME HEAT TREATMENT APPARATUS | August 2011 | November 2011 | Allow | 3 | 1 | 0 | No | No |
| 13192739 | CONTINUOUS CATALYTIC GENERATION OF POLYOLS FROM CELLULOSE | July 2011 | October 2012 | Allow | 14 | 2 | 0 | No | No |
| 13177476 | SUSTAINED RELEASE OF APO A-I MIMETIC PEPTIDES AND METHODS OF TREATMENT | July 2011 | January 2014 | Allow | 31 | 1 | 0 | No | No |
| 13175155 | Process for the Purification of Recombinant Albumin | July 2011 | March 2014 | Allow | 33 | 4 | 0 | No | No |
| 13126499 | MICROAEROBIC CULTURES FOR CONVERTING GLYCEROL TO CHEMICALS | June 2011 | November 2013 | Allow | 31 | 1 | 1 | Yes | No |
| 13160091 | NOVEL COLLECTIN | June 2011 | September 2013 | Allow | 27 | 0 | 0 | No | No |
| 13159124 | SHIGA TOXIN B-SUBUNIT AS A VECTOR FOR TUMOR DIAGNOSIS AND DRUG DELIVERY TO GB3 EXPRESSING TUMORS | June 2011 | July 2012 | Allow | 13 | 2 | 0 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner DESAI, ANAND U.
With a 100.0% reversal rate, the PTAB has reversed the examiner's rejections more often than affirming them. This reversal rate is in the top 25% across the USPTO, indicating that appeals are more successful here than in most other areas.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 28.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is below the USPTO average, suggesting that filing an appeal has limited effectiveness in prompting favorable reconsideration.
✓ Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner DESAI, ANAND U works in Art Unit 1655 and has examined 268 patent applications in our dataset. With an allowance rate of 99.3%, this examiner allows applications at a higher rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 38 months.
Examiner DESAI, ANAND U's allowance rate of 99.3% places them in the 93% percentile among all USPTO examiners. This examiner is more likely to allow applications than most examiners at the USPTO.
On average, applications examined by DESAI, ANAND U receive 2.23 office actions before reaching final disposition. This places the examiner in the 62% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.
The median time to disposition (half-life) for applications examined by DESAI, ANAND U is 38 months. This places the examiner in the 29% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.
Conducting an examiner interview provides a +0.9% benefit to allowance rate for applications examined by DESAI, ANAND U. This interview benefit is in the 19% percentile among all examiners. Note: Interviews show limited statistical benefit with this examiner compared to others, though they may still be valuable for clarifying issues.
When applicants file an RCE with this examiner, 34.4% of applications are subsequently allowed. This success rate is in the 76% percentile among all examiners. Strategic Insight: RCEs are highly effective with this examiner compared to others. If you receive a final rejection, filing an RCE with substantive amendments or arguments has a strong likelihood of success.
This examiner enters after-final amendments leading to allowance in 62.4% of cases where such amendments are filed. This entry rate is in the 87% percentile among all examiners. Strategic Recommendation: This examiner is highly receptive to after-final amendments compared to other examiners. Per MPEP § 714.12, after-final amendments may be entered "under justifiable circumstances." Consider filing after-final amendments with a clear showing of allowability rather than immediately filing an RCE, as this examiner frequently enters such amendments.
When applicants request a pre-appeal conference (PAC) with this examiner, 200.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 93% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences are highly effective with this examiner compared to others. Before filing a full appeal brief, strongly consider requesting a PAC. The PAC provides an opportunity for the examiner and supervisory personnel to reconsider the rejection before the case proceeds to the PTAB.
This examiner withdraws rejections or reopens prosecution in 95.5% of appeals filed. This is in the 85% percentile among all examiners. Of these withdrawals, 85.7% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.
When applicants file petitions regarding this examiner's actions, 35.3% are granted (fully or in part). This grant rate is in the 23% percentile among all examiners. Strategic Note: Petitions are rarely granted regarding this examiner's actions compared to other examiners. Ensure you have a strong procedural basis before filing a petition, as the Technology Center Director typically upholds this examiner's decisions.
Examiner's Amendments: This examiner makes examiner's amendments in 32.1% of allowed cases (in the 100% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 1.5% of allowed cases (in the 65% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.